: Tocotrienols, a subclass of compounds in the vitamin E family, significantly inhibits mitogen-induced proliferation and initiates apoptosis in preneoplastic and neoplastic mammary epithelial cells. These findings are particularly interesting because they were observed using treatment doses that had little or no effect on normal mammary epithelial cells growth or viability. In contrast, studies investigating the anticancer activity of tocopherols, the other vitamin E subclass, have shown for the most part, negative results. Determining the mechanism(s) mediating the antiproliferative and apoptotic effects of tocotrienols would provide essential information necessary for understanding the potential health benefits of these compounds in preventing and/or reducing the risk of breast cancer in women. The following aims are designed to determine the mechanism(s) mediating the antiproliferative and apoptotic effects of tocotrienols in normal and neoplastic mammary epithelial cells, with the goal of providing useful insights for basing effective strategies for use of tocotrienols in the prevention and treatment of breast cancer in women. 1) To determmentionedine tissue distribution and cellular concentrations of specific tocotrienols and correlate these findings with treatment effects on mitogenesis and apoptosis in normal, preneoplastic and neoplastic mammary epithelial cells in animals fed tocotrienol-supplemented diets. Absorption and distribution of tocopherols and tocotrienols is limited by the specificity and saturability of specific carrier protein and transport mechanisms within the body; 2) To determine the intracellular mechanism(s) mediating tocotrienol suppression of EGF-dependent mitogenic signaling in isolated normal, preneoplastic and neoplastic mammary epithelial cells in vitro. Since the initial events associated with EGF-dependent mitogenesis in mammary epithelial cells include protein kinase C, adenylate cyclase and cAMP-dependent protein activation, and tocotrienols have been shown to inhibit activation of these proteins in other cells types, it is possible that the antiproliferative effects of tocotrienols results from the inhibition of these mitogenic-signaling pathways; 3) To determine the intracellular signaling pathways responsible for mediating tocotrienol-induced apoptosis in normal, preneoplastic and neoplastic mammary epithelial cells. Various signaling pathways mediate vitamin E-dependent apoptosis in different cell types. Studies will be conducted to identify those apoptotic signaling pathways involved in tocotrienol-induced apoptosis, and whether or not similar signaling pathways are involved in mediating tocotrienol-induced apoptosis in, preneoplastic and neoplastic mammary epithelial cells.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Academic Research Enhancement Awards (AREA) (R15)
Project #
1R15CA086833-01A1
Application #
6357806
Study Section
Metabolic Pathology Study Section (MEP)
Program Officer
Crowell, James A
Project Start
2001-08-01
Project End
2004-07-31
Budget Start
2001-08-01
Budget End
2004-07-31
Support Year
1
Fiscal Year
2001
Total Cost
$124,500
Indirect Cost
Name
University of Louisiana at Monroe
Department
Type
Schools of Pharmacy
DUNS #
782279541
City
Monroe
State
LA
Country
United States
Zip Code
71209
Sylvester, Paul W; Ayoub, Nehad M (2013) Tocotrienols target PI3K/Akt signaling in anti-breast cancer therapy. Anticancer Agents Med Chem 13:1039-47
Sylvester, Paul W; Wali, Vikram B; Bachawal, Sunitha V et al. (2011) Tocotrienol combination therapy results in synergistic anticancer response. Front Biosci (Landmark Ed) 16:3183-95
Shirode, Amit B; Sylvester, Paul W (2011) Mechanisms Mediating the Synergistic Anticancer Effects of Combined ?-Tocotrienol and Celecoxib Treatment. J Bioanal Biomed 3:1-7
Sylvester, Paul W (2011) Optimization of the tetrazolium dye (MTT) colorimetric assay for cellular growth and viability. Methods Mol Biol 716:157-68
Sylvester, Paul W; Kaddoumi, Amal; Nazzal, Sami et al. (2010) The value of tocotrienols in the prevention and treatment of cancer. J Am Coll Nutr 29:324S-333S
Shirode, Amit B; Sylvester, Paul W (2010) Synergistic anticancer effects of combined gamma-tocotrienol and celecoxib treatment are associated with suppression in Akt and NFkappaB signaling. Biomed Pharmacother 64:327-32
Bachawal, Sunitha V; Wali, Vikram B; Sylvester, Paul W (2010) Combined gamma-tocotrienol and erlotinib/gefitinib treatment suppresses Stat and Akt signaling in murine mammary tumor cells. Anticancer Res 30:429-37
Bachawal, Sunitha V; Wali, Vikram B; Sylvester, Paul W (2010) Enhanced antiproliferative and apoptotic response to combined treatment of gamma-tocotrienol with erlotinib or gefitinib in mammary tumor cells. BMC Cancer 10:84
Samant, G V; Wali, V B; Sylvester, P W (2010) Anti-proliferative effects of gamma-tocotrienol on mammary tumour cells are associated with suppression of cell cycle progression. Cell Prolif 43:77-83
Wali, Vikram B; Bachawal, Sunitha V; Sylvester, Paul W (2009) Suppression in mevalonate synthesis mediates antitumor effects of combined statin and gamma-tocotrienol treatment. Lipids 44:925-34

Showing the most recent 10 out of 25 publications